TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial performance with reduced losses and consistent sales growth. The Q&A section supports this with plans for sales force expansion and strategic focus on new product launches and market positioning. Despite some expenses rising, the overall financial health appears stable. Additionally, management's confidence in meeting guidance and increased focus on patient-centric culture and reinforced tissue matrix contracts suggest positive future prospects. The lack of any major risks or uncertainties in management responses further supports a positive sentiment.
Key Financial Performance
Revenue for Q2 2025 $20.2 million, increased 26% year-over-year. Reasons for change: Growth in OviTex revenue by 12% and OviTex PRS revenue by 53%, with unit sales growth of 17% for OviTex and 40% for PRS.
Gross Margin for Q2 2025 69.8%, compared to 68.8% in the prior year period. Reasons for change: Primarily due to a lower charge for excess and obsolete inventory as a percentage of revenue.
Sales and Marketing Expense for Q2 2025 $16.9 million, compared to $16.7 million in the prior year period. Reasons for change: Higher commission expense on an increased revenue base, offset by lower compensation costs from a decrease in headcount and lower consulting and travel expenses.
General and Administrative Expense for Q2 2025 $4.1 million, compared to $3.6 million in the prior year period. Reasons for change: Not explicitly mentioned.
R&D Expense for Q2 2025 $2.2 million, compared to $2.3 million in the prior year period. Reasons for change: Not explicitly mentioned.
Loss from Operations for Q2 2025 $9.9 million, compared to $11.6 million in the prior year period. Reasons for change: Not explicitly mentioned.
Net Loss for Q2 2025 $9.9 million, compared to $12.6 million in the prior year period. Reasons for change: Not explicitly mentioned.
Cash and Cash Equivalents at the end of Q2 2025 $35 million. Reasons for change: Not explicitly mentioned.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
OviTex reinforced tissue matrix: Achieved over 73,000 units sold across the U.S. and Europe since launch, with significant scaling in hernia repair and abdominal wall reconstruction.
OviTex PRS portfolio: Scaled to more than 16,000 units sold in the U.S. since launch, focusing on plastic and reconstructive surgery.
LIQUIFIX non-penetrating fixation technology: Secured contracts with 3 major national GPOs, with 2 contracts awarding it an innovative technology designation. Achieved 121% year-over-year revenue growth.
OviTex IHR: Quarterly revenue grew 322% year-over-year and 29% sequentially. Launched in Europe in June, with anticipated further growth.
European market expansion: European sales grew 25% year-over-year, driven by 29% unit growth. Secured a 4-year framework agreement with the NHS in England for OviTex.
Educational initiatives: Targeting teaching hospitals and training programs to engage the next generation of surgeons, aiming for long-term returns.
Sales force optimization: Implemented a territory manager and account specialist model to improve resource allocation and engagement. Focused on patient-centric partnerships and surgeon education.
Data-driven decision-making: Introduced cost-effective data visualization tools to enhance territory management and account visibility.
Leadership changes: Appointed Jeff Blizzard as President to lead commercial strategy, leveraging his experience in MedTech and European markets.
Focus on patient outcomes: Shifted sales strategy to emphasize patient outcomes and surgeon engagement over transactional sales.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Environment: The company acknowledges the impact of macroeconomic conditions and changes in the regulatory environment, which could affect product development, pipeline opportunities, and operating performance.
Sales and Marketing Strategies: The company is transitioning from a transactional sales approach to a patient and outcome-centric model, which may pose challenges in execution and adoption by the sales team.
Territorial Inefficiencies: Certain territorial inefficiencies were identified, limiting clinical presence and sustained engagement efforts, which could impact revenue growth.
Market Development and Education: The company has not previously focused significant effort on targeting teaching hospitals and training programs, which could delay long-term returns from this initiative.
Competitive Pressures: Larger competitors have advantages in contracting and bundling, which could challenge TELA Bio's market positioning despite its operational flexibility and clinical consultation capabilities.
Sales Force Development: The company faces challenges in improving revenue per representative and ensuring the right cultural fit and capability profile among its sales team.
Economic Impact of Lower Recurrence Rates: Hospitals and administrators may weigh the economic impact of lower recurrence rates and improved patient satisfaction, which could influence the adoption of TELA Bio's products.
Financial Performance: The company reported a net loss of $9.9 million in Q2 2025, which, while an improvement from the prior year, still represents a financial challenge.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company is reiterating its full-year 2025 revenue guidance, anticipating revenue to be in the range of $85 million to $88 million, representing growth of 23% to 27% over the full year 2024.
Market Access and Growth: The company expects increased market access to contribute to further growth, particularly for LIQUIFIX and OviTex IHR. European sales grew 25% year-over-year in Q2, driven by 29% unit growth. The company anticipates further growth within the OviTex IHR portfolio following its European commercial launch in June.
Sales Strategy and Organizational Changes: The company is optimizing its sales force to improve resource allocation and management oversight. It is focusing on building patient and outcome-centric partnerships with healthcare providers, emphasizing surgeon engagement and education. The company is also targeting teaching hospitals and training programs to access the next generation of surgeons.
Product Development and Market Trends: The company is investing in education and engagement at teaching institutions to generate long-term returns as the market shifts away from plastic repair solutions. It is also focusing on demonstrating clinical expertise and achieving superior patient outcomes to build physician preference.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide an update on the sales force headcount, including the number of territory managers and account specialists, and any changes to expectations for 2025?
A:There are currently 69 territory managers and 25 account specialists, which has been a steady number. The plan is to rapidly reach the target of 76 territory managers. Four new candidates are in final interviews, and there are 7 positions to fill.
Q:Are there any changes to the cadence of revenues and operating expenses (OpEx) this year?
A:The cadence will follow historical patterns, with flattish growth from Q4 to Q1, a step-up from Q1 to Q2, slightly flatter growth from Q2 to Q3 due to summer holidays, and a bigger step-up from Q3 to Q4. OpEx is expected to remain largely flat quarter-to-quarter, with revenue growth contributing to bottom-line leverage.
Q:Can you elaborate on the focus on a patient-centric culture and areas where spending might be reduced or increased?
A:Spending reductions include revising the T&E policy and managing trunk stock and consignment to minimize waste. Investments will focus on recruiting the right hires in the right locations and ensuring the sales team has the clinical capability to support surgeons effectively.
Q:Can you provide more details on reinforced tissue matrix contracts and their impact on growth and adoption?
A:There are approximately 25 reinforced tissue matrix contracts in place, primarily with larger IDN systems. The strategy aims to establish a stand-alone product category outside of tiered pricing and bundling structures, supported by intellectual property protection and a patient-centric approach.
Q:What changes are being made to the selling strategy, and how will risks of commercial disruption be mitigated?
A:The focus is on reinforcing a patient-centric mentality rather than making significant changes. The team already possesses the right skill sets, and the goal is to remind them of their purpose. The TMAS model will continue to be supported, and open territories will be upgraded.
Q:Can you provide an update on demand trends for OviTex and its transition to a broad hernia portfolio provider?
A:OviTex is transitioning from focusing on complex abdominal wall reconstruction to offering a full-service hernia portfolio, including inguinal procedures. The transition involves gaining traction in lower ASP, high-incidence procedures while maintaining growth in complex cases. The goal is to execute across the entire hernia spectrum.
Q:What drove the positive results and volume growth for OviTex PRS, and where did the ASP lift come from?
A:Positive results were driven by the launch of large long-term resorbable PRS products and the availability of published clinical data. The ASP lift came from the new large PRS products, which align with the launch of large-sized implants. More PRS products are expected in the future to broaden the portfolio.
Q:What gives you confidence in the guidance, particularly the acceleration in Q4?
A:The natural back-weighting of sales in Q4 is due to factors like health savings account usage, year-end targets for sales reps and physicians, and holiday scheduling. The sequential growth required is similar to what was achieved in Q2, and new hires are expected to contribute to growth.
Q:Can you provide details on the split between teaching and non-teaching hospitals and the runway for growth in these groups?
A:A third party, MedScout, is helping identify key teaching programs. The refined roster will be available in Q3 to implement the strategy, and there is significant potential for growth in both teaching and non-teaching hospitals.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were direct and provided sufficient detail.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Abiomed
Blizzard President
Director
Dr
GPO
IHR
Johnson
LIQUIFIX
LLC Research
Meeting
NHS
PRS portfolio
Research Division
Robotic
Society
approach
area
complication
contracting
culture
education
effort
experience
expertise
flap
health
hernia repair
initiative
market access
month
observation
outcome
placement
policy
presentation
profile
publication
recurrence rate
wall reinforcement
year cohort
TELA Transcript
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary reveals strong financial performance with a 25% YoY revenue increase and improved gross margins. Despite regulatory and market challenges, the company shows resilience with reduced net loss and strategic initiatives for product development. The lack of guidance or shareholder return details is a concern, but the financial metrics and growth potential in Europe suggest a positive outlook. The stock price is likely to experience a positive movement of 2% to 8% over the next two weeks, assuming a neutral market cap impact.
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call reflects mixed signals. While there are improvements in losses and cash flexibility, the reduced guidance and uncertainties due to organizational changes and external factors like weather impact sentiment negatively. The Q&A highlighted management's cautious approach and lack of clarity in some responses, further contributing to a neutral outlook. The absence of strong positive catalysts or partnerships limits the potential for a significant stock price increase.
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed performance, with stable gross margins and reduced losses but lowered guidance for 2025, indicating potential challenges. The Q&A highlights uncertainties, particularly with unclear management responses and the need for refinancing and equity raises, suggesting financial strain. Despite some positive growth in Europe and a strong sales force, the lack of precise future growth details and a lowered guidance contribute to a negative sentiment, likely impacting the stock price negatively in the short term.
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Positive8-11
The earnings call indicates strong financial performance with reduced losses and consistent sales growth. The Q&A section supports this with plans for sales force expansion and strategic focus on new product launches and market positioning. Despite some expenses rising, the overall financial health appears stable. Additionally, management's confidence in meeting guidance and increased focus on patient-centric culture and reinforced tissue matrix contracts suggest positive future prospects. The lack of any major risks or uncertainties in management responses further supports a positive sentiment.
TELA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
